Rabbit Polyclonal OLFML2A Antibody

+ +

•  

   
     Western blot analysis of MRPS18A expression in HEK293T, Raw264.7, H9C2 whole cell lysates.    

•  

   
     Immunofluorescent analysis of OLFML2A staining in HepG2 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).    

•  

   
     Immunohistochemical analysis of OLFML2A staining in human brain formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.    

OLFML2A (olfactomedin-like 2A) is a secreted glycoprotein belonging to the olfactomedin domain-containing protein family, implicated in extracellular matrix organization and modulation of cellular signaling pathways. It interacts with BMP (bone morphogenetic protein) and Wnt signaling components, influencing tissue development, angiogenesis, and immune regulation. OLFML2A is expressed in various tissues, including the eye, placenta, and vascular endothelium, with roles in embryonic development and tissue homeostasis. Dysregulation of OLFML2A has been linked to pathologies such as cancer, inflammatory diseases, and retinopathies.

Antibodies targeting OLFML2A are essential tools for studying its expression, localization, and function. They enable detection via techniques like Western blot, immunohistochemistry, and ELISA, aiding research into its mechanistic contributions to diseases. For instance, OLFML2A overexpression in certain cancers correlates with tumor progression and angiogenesis, making it a potential therapeutic target or biomarker. Recent studies also explore its involvement in modulating immune cell activity and vascular remodeling.

Commercial OLFML2A antibodies are typically developed using recombinant protein fragments or synthetic peptides as immunogens, validated for specificity across human and model organisms. Challenges include ensuring minimal cross-reactivity with homologous family members (e.g., OLFML2B). Ongoing research aims to clarify its dual roles in pro- and anti-inflammatory contexts, highlighting its complexity in disease pathways. These antibodies thus serve as critical reagents for both basic research and translational applications.